




# PHARMACEUTICAL 2018

RespireRx Pharmaceuticals Inc.  
Rank 335 of 342





# PHARMACEUTICAL 2018

RespireRx Pharmaceuticals Inc.  
Rank 335 of 342

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 502% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 303% points.

The company's Economic Capital Ratio, given in the ranking table, is -497%, being 542% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	177
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,550
Liabilities, Non-Current	0
Other Assets	18
Other Compr. Net Income	0
Other Expenses	102
Other Liabilities	0
Other Net Income	58
Other Revenues	0
Property and Equipment	0
Research and Development	1,732
Selling, General and Administrative Expense	2,516

Output Variable	Value in 1000 USD
Assets	195
Liabilities	4,550
Expenses	4,350
Revenues	0
Stockholders Equity	-4,355
Net Income	-4,291
Comprehensive Net Income	-4,291
Economic Capital Ratio	-497%